Target symptoms including hot flashes, mood changes, trouble sleeping, and more
Once commercially available (expected late 2026-2027), brand-name retatrutide pricing will likely mirror or exceed tirzepatide pricing, given Eli Lilly manufactures both compounds and the market dynamics of premium obesity medications
This triple mechanism does not treat a disease endpoint it reprograms the metabolic environment in which obesity, type 2 diabetes, MASH, cardiovascular disease, and multiple chronic conditions emerge and progress
The injection allows for a consistent amount of the medication to be injected and absorbed in your body throughout the week
This measurement reflects average glucose over the preceding 8-12 weeks and isnt affected by daily fluctuations or single meal choices